Panel Based MALDI-TOF Tumour Profiling Is a Sensitive Method for Detecting Mutations in Clinical Non Small Cell Lung Cancer Tumour

Open Access

Peer-reviewed

Research Article

James L. Sherwood ,

* E-mail: James.Sherwood@AstraZeneca.com

Affiliation Personalised Healthcare & Biomarkers, AstraZeneca, Macclesfield, United Kingdom
⨯
Susanne Müller,

Affiliation Sequenom GmbH, Hamburg, Germany
⨯
Maria C. M. Orr,

Affiliation Personalised Healthcare & Biomarkers, AstraZeneca, Macclesfield, United Kingdom
⨯
Marianne J. Ratcliffe,

Affiliation Personalised Healthcare & Biomarkers, AstraZeneca, Macclesfield, United Kingdom
⨯
Jill Walker

Affiliation Personalised Healthcare & Biomarkers, AstraZeneca, Macclesfield, United Kingdom
⨯

Reader Comments (1)

Matrix-assisted laser desorption ionization time-of-flight mass spectrometry
Is the Subject Area "Matrix-assisted laser desorption ionization time-of-flight mass spectrometry" applicable to this article?

Thanks for your feedback.
Mutation detection
Is the Subject Area "Mutation detection" applicable to this article?

Thanks for your feedback.
Non-small cell lung cancer
Is the Subject Area "Non-small cell lung cancer" applicable to this article?

Thanks for your feedback.
Amplification-refractory mutation system analysis
Is the Subject Area "Amplification-refractory mutation system analysis" applicable to this article?

Thanks for your feedback.
Mutation databases
Is the Subject Area "Mutation databases" applicable to this article?

Thanks for your feedback.
Lung and intrathoracic tumors
Is the Subject Area "Lung and intrathoracic tumors" applicable to this article?

Thanks for your feedback.
Adenocarcinoma
Is the Subject Area "Adenocarcinoma" applicable to this article?

Thanks for your feedback.
Cutaneous melanoma
Is the Subject Area "Cutaneous melanoma" applicable to this article?

Thanks for your feedback.